News

Doping for UK's biomedicine
Enlarge image

BusinessUK

Doping for UK's biomedicine

03.08.2012 - The UK government has pledged to invest additional €49m (£39m) in the country's life science research.

The Biomedical Catalyst Fund commited €12,6m (£10m) to 14 universities and 18 small- and medium-sized enterprises (SMEs) to explore the market potential of early-stage ideas. Each of the universities received up to £750k, while each company received up to £150k to propel their projects. These are the first investments for the three-year, €227m (£180m) fund. It is part of the Strategy for Life Science unveiled by UK’s Prime Minister David Cameron December last year to foster the domestic life science industry. The grants will fund about 150 pilot projects, allowing academic researchers to begin the process of turning a bright idea into a viable proposition. Universities have control over allocating the funding internally, allowing them to respond rapidly to new opportunities and have the flexibility to pursue the most promising translational research opportunities.

In an effort to establish four e-health centres of excellence in London, Manchester, Dundee and Swansea, UK’s Medical Research Council has teamed up with a consortium of ten public and charity research funders. The centres will focus on conditions including cancer, diabetes, obesity and cardiovascular disease. The researchers working at these centers will link information in NHS health records with other forms of research and routinely-collected data to improve patient care and public health.

Only days ago, Cameron unveiled plans to converse the Olympic drug testing laboratories located in Harlow into a phenome research centre after the Games are complete. The concept of the phenome encapsulates all of an individual’s traits, which are the outcome of a continuous interplay between their genes and the environment. It will be funded by €12,6m (£10m) investments over five years by both the Medical Research Council and the Department of Health’s National Institute for Health Research. Two companies who make scientific instruments - Bruker, and Waters Corporation – will invest additional €25,2m (£20m). Imperial College and King’s College London will be academic partners in the project.

BusinessSpainUKSweden

31.07.2014 Astrazeneca is buying the rights to Almirall’s respiratory drugs in a deal worth up to €1.56bn.

BusinessFranceGermanySwitzerlandUK

30.07.2014 Rumours have it that French Danone wants to sell its medical nutrition business to US drugmaker Hospira for US$5bn in yet another tax inversion deal.

RegulationUKEU

29.07.2014 The first vaccine for malaria may be within reach: The European Medicines Agency has accepted Glaxosmithkline’s malaria vaccine candidate RTS,S for regulatory review.

FundingEU

25.07.2014 The European Commission aims to support innovation in Europe and announced a "Fast Track to Innovation" pilot as well as five innovation prices under Horizon 2020.

ResearchUKEU

23.07.2014 In the largest genomic study published on any psychiatric disorder so far, researchers have indentified 83 new locations in the human genome associated with the risk of developing schizophrenia.

BusinessUKIreland

21.07.2014 Abbvie’s tenacious pursuit of British rival Shire is finally paying off: The two companies have unveiled their transatlantic merger worth £32bn (€40bn).

ResearchEUSwitzerland

17.07.2014 A trans-border, cross-disciplinary project that aims to model the human brain in a computer has drawn heavy criticism from scientists pledging to boycott the project.

MergerUK

16.07.2014 After rejecting three merger propositions from US competitor Abbvie, Shire has now given up resistance to the deal and is recommending a new and improved offer worth £31.3bn.

AcquisitionUKDenmarkSpainGermanyFrance

15.07.2014 British specialty pharma company Prostrakan is handing over £230m for Archimedes Pharma Limited, a company that brings its lead product Pecfent and its proprietary drug delivery technology platform into the deal.

FundingEU

11.07.2014 Among the seven newly launched Joint Technology Initiatives (JTI) of Horizon2020 are two with deep roots in biotech: IMI is going into its second round while the newly established Bio-based Industries partnership invests in bioeconomy.

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • SUMMIT (UK)4.03 GBP3.87%
  • ZELTIA (E)2.89 EUR3.58%
  • 4SC (D)1.30 EUR0.00%

FLOP

  • ANTISOMA (UK)1.32 GBP-14.84%
  • XENETIC BIOSCIENCES (UK)6.00 GBP-14.29%
  • STENTYS (F)6.36 EUR-12.40%

TOP

  • WILEX (D)2.70 EUR221.4%
  • NEUROVIVE PHARMACEUTICAL AB (S)74.00 SEK49.8%
  • Allergy Therapeutics (UK)20.00 GBP33.3%

FLOP

  • HYBRIGENICS (F)1.57 EUR-33.2%
  • STENTYS (F)6.36 EUR-30.0%
  • PROTHENA PLC (IE)17.36 USD-23.2%

TOP

  • SANTHERA (CH)59.90 CHF2836.3%
  • GW PHARMACEUTICALS (UK)418.50 GBP634.2%
  • PAION (D)2.50 EUR290.6%

FLOP

  • EVOCUTIS (UK)0.21 GBP-93.0%
  • CYTOS (CH)0.27 CHF-92.0%
  • THROMBOGENICS (B)9.07 EUR-71.3%

No liability assumed, Date: 01.08.2014